Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from vTv Therapeutics ( (VTVT) ).
On June 10, 2025, vTv Therapeutics Inc. held its 2025 Annual Meeting of Stockholders, where the company’s stockholders elected several nominees to the Board of Directors for terms expiring at the 2026 annual meeting. Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. These decisions are expected to influence the company’s governance and financial oversight in the coming year.
The most recent analyst rating on (VTVT) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on vTv Therapeutics stock, see the VTVT Stock Forecast page.
Spark’s Take on VTVT Stock
According to Spark, TipRanks’ AI Analyst, VTVT is a Underperform.
vTv Therapeutics’ overall stock score reflects significant financial difficulties and a speculative valuation, balanced by positive developments in its clinical trials. While the corporate events suggest future potential, the current financial instability and lack of profitability weigh heavily on the stock’s attractiveness.
To see Spark’s full report on VTVT stock, click here.
More about vTv Therapeutics
vTv Therapeutics Inc. operates in the biotechnology industry, focusing on the development of orally administered small molecule drug candidates for the treatment of a range of human diseases.
Average Trading Volume: 20,001
Technical Sentiment Signal: Sell
Current Market Cap: $53M
Find detailed analytics on VTVT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue